Edding Genor Group Holdings Limited Overview
- Year Founded
-
2001
- Status
-
Public
- Employees
-
1,499
- Stock Symbol
-
06998
- Investments
-
2
- Share Price
-
$0.20
- (As of Friday Closing)
Edding Genor Group Holdings Limited General Information
Description
Edding Genor Group Holdings Ltd is an integrated specialty biopharmaceutical company, focusing on oncology, autoimmune diseases, cardiovascular diseases, respiratory diseases, and anti-infectives. Through the acquisition of branded drug assets from multinational pharmaceutical companies (MNCs) and licensing in development and commercialisation rights of patented drugs from international biopharmaceutical companies, it has established a portfolio of originator-branded and other drugs. The company has two reportable operating segments: Manufacturing and Distribution, which generates the maximum revenue, and Research and development. Geographically, it derives maximum revenue from the Chinese mainland, and the rest from the USA and other markets.
Contact Information
Website
www.eddingpharm.comCorporate Office
- Units 122-129, Building A3
- Number 700 Wanrong Road, Jing'an District
- Shanghai, 200072
- China
Corporate Office
- Units 122-129, Building A3
- Number 700 Wanrong Road, Jing'an District
- Shanghai, 200072
- China
Edding Genor Group Holdings Limited Stock Performance
As of 13-Nov-2026, Edding Genor Group Holdings Limited’s stock price is $0.20. Its current market cap is $389M with 1.97B shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.20 | $0.19 | $0.18 - $0.46 | $389M | 1.97B | 771K | $0.02 |
Edding Genor Group Holdings Limited Financials Summary
As of 30-Jun-2026, Edding Genor Group Holdings Limited has a trailing 12-month revenue of $318M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 482,610 | |||
| Revenue | 317,927 | 345,898 | 354,827 | 307,928 |
| EBITDA | 94,684 | 120,149 | 127,872 | |
| Net Income | 31,278 | 55,520 | 54,057 | |
| Total Assets | 896,446 | 943,665 | 745,200 | |
| Total Debt | 174,033 | 212,457 | 278,644 |
Edding Genor Group Holdings Limited Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Edding Genor Group Holdings Limited Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Edding Genor Group Holdings Limited Patents
Edding Genor Group Holdings Limited Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024292559-A1 | Anti-pd-1/ctla-4/vegf antibodies and use thereof | Pending | 14-Jul-2023 | ||
| EP-4743496-A1 | Anti-pd-1/ctla-4/vegf antibodies and use thereof | Pending | 14-Jul-2023 | ||
| JP-2026524215-A | Anti-pd-1/ctla-4/vegf antibody and its use | Pending | 14-Jul-2023 | ||
| US-10085973-B2 | Pharmaceutical composition containing a compound having a thrombopoietin receptor agonistic activity | Active | 29-Jun-2012 | ||
| US-20160317506-A1 | Pharmaceutical composition containing a compound having a thrombopoietin receptor agonistic activity | Active | 29-Jun-2012 | A61K31/426 |
Edding Genor Group Holdings Limited Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Edding Genor Group Holdings Limited Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Edding Genor Group Holdings Limited Investments & Acquisitions (2)
Edding Genor Group Holdings Limited’s most recent deal was a Corporate Asset Purchase with Eli Lilly and Company (Manufacturing facility in Suzhou and Rights in China for Ceclor & Vancocin) for . The deal was made on 22-Apr-2019.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Eli Lilly and Company (Manufacturing facility in Suzhou and Rights in China for Ceclor & Vancocin) | 22-Apr-2019 | Corporate Asset Purchase | Buildings and Property | ||
| ACT Biotech (Molecule Drug Assets) | 19-Feb-2014 | Merger/Acquisition | Drug Discovery |
Edding Genor Group Holdings Limited ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Edding Genor Group Holdings Limited FAQs
-
When was Edding Genor Group Holdings Limited founded?
Edding Genor Group Holdings Limited was founded in 2001.
-
Where is Edding Genor Group Holdings Limited headquartered?
Edding Genor Group Holdings Limited is headquartered in Shanghai, China.
-
What is the size of Edding Genor Group Holdings Limited?
Edding Genor Group Holdings Limited has 1,499 total employees.
-
What industry is Edding Genor Group Holdings Limited in?
Edding Genor Group Holdings Limited’s primary industry is Pharmaceuticals.
-
Is Edding Genor Group Holdings Limited a private or public company?
Edding Genor Group Holdings Limited is a Public company.
-
What is Edding Genor Group Holdings Limited’s stock symbol?
The ticker symbol for Edding Genor Group Holdings Limited is 06998.
-
What is the current stock price of Edding Genor Group Holdings Limited?
As of 13-Nov-2026 the stock price of Edding Genor Group Holdings Limited is $0.20.
-
What is the current market cap of Edding Genor Group Holdings Limited?
The current market capitalization of Edding Genor Group Holdings Limited is $389M.
-
What is Edding Genor Group Holdings Limited’s current revenue?
The trailing twelve month revenue for Edding Genor Group Holdings Limited is $318M.
-
What is Edding Genor Group Holdings Limited’s annual earnings per share (EPS)?
Edding Genor Group Holdings Limited’s EPS for 12 months was $0.02.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
